Rexahn Pharmaceuticals, Inc. (AMEX: RNN), a leader in innovative therapeutics for life-threatening and life-debilitating diseases, announced that the Company has received FDA approval to begin Phase II trials for Serdaxin™, for the treatment of major depressive disorders (MDD).
This trial represents the third Phase II study currently in progress at Rexahn Pharmaceuticals. Read the rest of this entry »
Archive for November 24, 2008
Research has shown that one in 10 women in the U.S. experience postpartum depression, and "South Asian women — particularly newer immigrants — may be at a higher risk for [postpartum depression], because of difficulties adjusting to a new culture, loneliness, isolation and the lack of a traditional Indian support system," New Read the rest of this entry »
UroToday.com - Treatment emergent sexual dysfunction is a frequent adverse effect occurring with medication use and is a major influence for premature treatment discontinuation, which leads to treatment failure and costly disease management outcomes.
Sexual dysfunction is recognized as being associated with selective and nonselective serotonin reuptake inhibitor (SRI) antidepressants, the most frequently prescribed medications Read the rest of this entry »